xerispharma.com (XERS) Quarterly EPS earnings growth

Symbol and logo of brand Xeris Pharma (XERS)

Xeris Biopharma (XERS) innovations in XeriSol stable injections create a foundation for the development of niche endocrine agents, as evidenced by the quarterly EPS growth. The 1593.60 metric confirms the asset's current level of neutral dynamics. The strategy is completed by the use of external partners for drug manufacturing and testing, which allows the company to optimize staffing and expand drug distribution.

XERS: Xeris Biopharma Holdings Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 11/17/2026

Xeris Biopharma (XERS) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:Xeris Biopharma
Flagship merchandise of Xeris Pharma

The long-term reliability of Xeris Biopharma (XERS) is determined by its ability to generate a sustainable cash flow per share. This metric measures the rate of change in quarterly net income, revealing hidden imbalances within financial statements. By analyzing quarterly EPS progress, an investor assesses the efficiency of operating profitability. This price action reflects management's success in optimizing commercial expenses, confirming the company's movement toward full self-sufficiency.

Who Xeris Biopharma competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Keros Therapeutics - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months ARCT (Arcturus Therapeutics)|ETON: Quarterly EPS earnings growth|Kamada Ltd (KMDA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Fulcrum Tx|ABEO: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Mereo BioPharma Group (MREO)|Quarterly EPS earnings growth protalix.com (PLX)|Quarterly EPS earnings growth PLRX (Pliant Therapeutics Inc)|Quarterly EPS earnings growth Applied Therapeutics APLT|RNTX - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year gelteq.com (GELS)|AYTU (aytubio.com) - Year-over-year net earnings per share growth for the last 12 months|Chemomab Therapeutics Ltd - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SRXH|Year-over-year earnings per share growth for the last twelve months PLRZ|Quarterly EPS earnings growth AEZS|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth